Ocular adverse events associated with GLP-1 receptor agonists: a real-world study based on the FAERS database and network pharmacology

Among 17,785,793 FAERS reports, semaglutide and lixisenatide were significantly associated with ocular adverse events.

• Semaglutide had a reporting odds ratio (ROR) of 1.25, indicating a potential increase in ocular adverse events.
• Lixisenatide had a higher ROR of 1.96, suggesting an even greater association with ocular adverse events.
• Common ocular adverse events included blurred vision, visual impairment, and diabetic retinopathy.
• Some ocular adverse events were reported as early as 10 days after treatment initiation.
• Gene enrichment analysis suggested potential links between GLP-1-related genes and the occurrence of ocular adverse events.

AI simplified